Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DS-5670d (duvofameran)
- Development stage
- Unknown
- Lead developer
- Daiichi Sankyo
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intramuscular
01
Overview
DS-5670d (duvofameran) is a monovalent mRNA vaccine developed by Daiichi Sankyo for the prevention of COVID-19, specifically targeting the Omicron XBB.1.5 variant. It utilizes a proprietary lipid nanoparticle (LNP) delivery system to transport mRNA encoding the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein into host cells. Unlike some other mRNA vaccines that encode the full-length spike protein, DS-5670d focuses on the RBD to potentially enhance the precision of the immune response. Once translated by host cells, the RBD antigen stimulates the production of neutralizing antibodies and activates cellular immunity. It was approved in Japan in November 2023 as a booster dose for individuals aged 12 years and older.
- Brand names
- Daichirona
- Other names
- Daiichi Sankyo COVID-19 mRNA vaccine (Omicron XBB.1.5)
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on DS-5670d (duvofameran).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DS-5670d (duvofameran).